DRF 1042
Alternative Names: DRF-1042Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Dr Reddys Laboratories
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in India (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 31 Mar 2010 DRF 1042 is still in phase I development in India